HAQ
|
1.06 (0.73)
|
1.00 (0.50 to 1.62)
|
0.00 to 3.00
| | |
PCS
|
35.8 (11.0)
|
34.7 (27.3 to 44.1)
|
6.5 to 69.4
|
46.2 (3.4)
|
40.2 to 55.3
|
MCS
|
49.0 (11.3)
|
51.4 (40.7 to 58.0)
|
7.6 to 75.2
|
50.8 (1.46)
|
45.0 to 52.7
|
EQ-5D
|
0.73 (0.19)
|
0.78 (0.69 to 0.83)
|
-0.11 to 1.00
|
0.83 (0.03)
|
0.79 to 0.93
|
Age (years)
|
59.9 (13.0)
| | | | |
Sex (% male)
|
23.3
| | | | |
Non-Hispanic White (%)
|
89.8
| | | | |
High school graduate (%)
|
89.4
| | | | |
College graduate (%)
|
26.3
| | | | |
Income (median $US)
|
35,000
| | | | |
RA duration (median IQR) years
|
9.7 (4.4 to 18.1)
| | | | |
Study duration (years)
|
3.7 (3.2)
| |
0.5 to 11.0
| | |
Study duration biologic comparison) (years)
|
6.1 (3.0)
| |
1.0 to 11.0
| | |
Comorbid conditions (none) (%)
|
27.2
| | | | |
Comorbid conditions (1) (%)
|
27.1
| | | | |
Comorbid conditions (≥ 2) (%)
|
45.8
| | | | |
Satisfied or very satisfied with health (%)
|
51.5
| | | | |
MTX (%)
|
47.8
| | | | |
MTX (anytime in study) (%)
|
60.8
| | | | |
Prednisone (%)
|
40.5
| | | | |
Biologic (anytime in study) (%)
|
44.5
| | | | |
DMARD use (lifetime) (%)
|
92.3
| | | | |
Triple therapy (lifetime) (%)
|
3.7
| | | | |